The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA's approval is based on the results of the FLOW phase 3b kidney outcomes trial. The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly.

My doctor increased my dose to 1.7 mg of Wegovy instead of 2 mg of Ozempic. I find myself continuing to crave sweets and have gained 8 pounds in around six months. I’m wondering if any studies e ...